Long-term Ocular Safety in Children Treated with MAPK Pathway Inhibitor Therapy [0.03%]
儿童MAPK通路抑制剂治疗的长期眼部安全性
Robert A Avery,Andrea M Gross,Chantal Cousineau-Krieger et al.
Robert A Avery et al.
A Novel Staging Model for Uveal Melanoma: Combining Tumor Volume, Clinical Factors, and Genetic Alterations in a Danish Cohort [0.03%]
丹麦队列中葡萄膜黑色素瘤的新分期模型：结合肿瘤体积、临床因素和遗传改变
Kristoffer Nissen,Tine Gadegaard Hindso,Carsten Faber et al.
Kristoffer Nissen et al.
Importance: Uveal melanoma classification systems based on anatomical location show limitations in risk stratification and create ambiguities when tumors span multiple uveal regions. ...
Adolescent Malignant Uveal Melanoma with SMARCB1 Deficiency and Orbital Invasion [0.03%]
伴有视神经侵犯的SMARCB1缺陷青少年恶性脉络膜黑色素瘤病例报告
Xiaotong Sha,Zhenguo Xiao,Lijun Shen
Xiaotong Sha
Ocular Hypertension and Glaucoma After Pars Plana Vitrectomy: A Systematic Review and Meta-analysis [0.03%]
玻璃体切割术后高眼压和青光眼的系统评价和meta分析研究
Gabriele Gallo Afflitto,Lorenzo Fabozzi,Filomena Palmieri et al.
Gabriele Gallo Afflitto et al.
Topic: To evaluate whether pars plana vitrectomy (PPV) increases the risk of ocular hypertension (OHT) and glaucoma, with particular focus on lens status as a risk modifier. ...
Oral acetylcysteine and the risk of age-related macular degeneration: A retrospective cohort study [0.03%]
口服乙酰半胱氨酸与年龄相关性黄斑变性疾病风险的回顾性队列研究
Hou-Ren Tsai,Wei-Chuan Chang,Yuan-Chieh Lee
Hou-Ren Tsai
Purpose: N-acetylcysteine (NAC) functions as both a direct antioxidant agent and precursor for glutathione synthesis, both of which are implicated in the pathogenesis of age-related macular degeneration (AMD). However, wh...
Six-year rate of visual field progression in the Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial [0.03%]
激光治疗青光眼和高眼压症(LiGHT)试验中6年的视野进展速率
Giovanni Montesano,David P Crabb,David F Garway-Heath et al.
Giovanni Montesano et al.
Purpose: to compare the 6-year rate of visual field (VF) progression in the two arms of the Laser in Ocular Hypertension and Glaucoma Trial (LiGHT), comparing selective laser trabeculoplasty (SLT) and drops as first treat...
Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal Studies COMET-2 and COMET-3 [0.03%]
艾克司蒙眼科用药0.003％治疗干眼病的症状和体征III期研究COMET-2及COMET-3结果
Guruprasad R Pattar,David Wirta,Gary Jerkins et al.
Guruprasad R Pattar et al.
Purpose: Evaluate safety and efficacy of the novel transient receptor potential melastatin 8 agonist acoltremon on signs and symptoms of dry eye disease (DED). ...
Treating retinopathy of prematurity with dexamethasone eye drops: a difference-in-differences study in Sweden using register data [0.03%]
瑞典一项基于登记数据的差值差异研究：用肾上腺皮质激素滴眼液治疗早产儿视网膜病变
Lotta Akc Gränse,Hanna Maria V Öhnell,Gerd Holmström et al.
Lotta Akc Gränse et al.
Objective: To estimate the effect of dexamethasone eye drops on the risk of progression from type 2 retinopathy of prematurity (ROP) to ROP requiring traditional treatments. ...
Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Non-infectious Uveitis: A Multi-Center Study [0.03%]
评估阿达木单抗滴定治疗非感染性葡萄膜炎的多中心研究：每周一次剂量升级的有效性分析
Shani Pillar,Akshay Thomas,Lynn Hassman et al.
Shani Pillar et al.
Purpose: To evaluate the effectiveness of adalimumab (ADA) dose escalation in patients with non-infectious uveitis who are inadequately controlled with standard dosing. ...
Industry Financial Relationships of Presenters at the American Academy of Ophthalmology Annual Meeting with an Emphasis on Consultants [0.03%]
美国眼科年会报告人的行业财务关系：注重咨询机构的关系
Roni M Shtein,Kerby Shedden,Alyssa A Horstman et al.
Roni M Shtein et al.
Objective: To assess industry financial relationships of ophthalmologist presenters at the American Academy of Ophthalmology (AAO) Annual Meeting between 2016 and 2020. ...